🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

10,225 results for “He” Clear

  1. TUCATINIB, CAPECITABINE, TUCATINIB, RO7771950, RO7771950, TRASTUZUMAB, CAPECITABINE, TRASTUZUMAB

    Hoffmann-La Roche

    Pretreated Unresectable Locally Advanced or Metastatic human epidermal growth factor receptor 2 (HER2)-Positive Breast Cancer, with or without Central Nervous System (CNS) Metastases

    phase 3 small molecule active

    1 trial

  2. TX200-TR101

    SANGAMO THERAPEUTICS, INC

    Kidney Transplant Rejection

    phase 3 small molecule active

    1 trial

  3. TachoSil®

    Takeda

    Hemorrhage

    phase 3 mab completed

    1 trial

  4. Tacrolimus BID

    Teva Pharma GmbH

    Medication Adherence

    phase 3 small molecule active

    1 trial

  5. Tacrolimus capsule

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Myasthenia Gravis

    phase 3 small molecule completed

    1 trial

  6. Tacrolimus capsule

    Astellas Pharma Inc

    Myasthenia Gravis

    phase 3 small molecule completed

    1 trial

  7. Tadalafil

    United Therapeutics Europe Ltd

    Pulmonary Hypertension

    phase 3 small molecule completed

    1 trial

  8. Tamiflu 75 mg hard capsules, DOLIPRANE 1000 mg, poudre pour solution buvable en sachet-dose

    Pari Pharma GmbH

    Adult patients admitted to the ICU for management of severe influenza infection requiring orotracheal intubation for invasive mechanical ventilation

    phase 3 small molecule active

    1 trial

  9. Tamoxifen

    International Peace Maternity and Child Health Hospital

    Breast Cancer

    phase 3 small molecule completed

    1 trial

  10. Tamoxifen Viatris 20 mg tabletter.

    The George Institute

    Breast Cancer

    phase 3 small molecule active

    1 trial

  11. Targeting Normoxemia (SpO2 90-96%; PaO2 60-100 mmHg)

    United Therapeutics Europe Ltd

    Critical Illness

    phase 3 other active

    2 trials

  12. Tarlatamab, OXALIPLATINE VIATRIS 5 mg/ml, poudre pour solution pour perfusion, Dacarbazine "Lipomed", Tecentriq 1 200 mg concentrate for solution for infusion, Docetaxel Accord 80 mg/4 ml concentrate for solution for infusion, Temozolomide 100 mg hard capsules, OPDIVO 10 mg/mL concentrate for solution for infusion., KEYTRUDA 25 mg/mL concentrate for solution for infusion, Topotecan Accord Healthcare 4mg Powder for Concentrate for Solution for Infusion, IRINOTECAN VIATRIS 20 mg/ml, solution à diluer pour per

    CERO THERAPEUTICS HOLDINGS, INC.

    Advanced pulmonary or gastroenteropancreatic poorly differentiated neuroendocrine carcinomas (NECs)

    phase 3 small molecule active

    1 trial

  13. Taselisib

    Hoffmann-La Roche

    Breast Cancer

    phase 3 small molecule terminated

    1 trial

  14. Tasimelteon

    Vanda Pharmaceuticals Netherlands B.V.

    Sleep Wake Disorders

    phase 3 small molecule active

    2 trials

  15. Tasimelteon

    Vanda Pharmaceuticals Netherlands B.V.

    Jet Lag Type Insomnia

    phase 3 small molecule completed

    1 trial

  16. Tasimelteon Oral Capsule, Tasimelteon Liquid Suspension

    Vanda Pharmaceuticals Netherlands B.V.

    Autism Spectrum Disorder

    phase 3 small molecule active

    1 trial

  17. Tasimelteon Oral Suspension

    Vanda Pharmaceuticals Netherlands B.V.

    Insomnia Disorder

    phase 3 small molecule active

    1 trial

  18. Taxane

    Hoffmann-La Roche

    Gastric Cancer

    phase 3 small molecule terminated

    1 trial

  19. Tbo-filgrastim

    Teva Pharma GmbH

    Healthy Participants

    phase 3 small molecule terminated

    1 trial

  20. Tebipenem pivoxil, SODIUM CHLORIDE, IMIPENEM AND CILASTATIN , Placebo to match Tebipenem pivoxil, tablet

    Spero Therapeutics

    complicated urinary tract infection (cUTI) or acute pyelonephritis (AP)

    phase 3 small molecule active

    1 trial

  21. Tecentriq 1 200 mg concentrate for solution for infusion

    Ningbo Cancer Hospital

    High-risk non-muscle invasive bladder cancer (NMIBC) after transurethral resection of the bladder (TURBT) and pathological assessment.

    phase 3 small molecule active

    1 trial

  22. Tecentriq 1 200 mg concentrate for solution for infusion

    Hoffmann-La Roche

    Cancer (Future parent protocols may include other cancer that are not included in this section)

    phase 3 small molecule active

    1 trial

  23. Tecentriq 1 200 mg concentrate for solution for infusion, Avastin 25 mg/ml concentrate for solution for infusion.

    Hoffmann-La Roche

    High-risk hepatocellular carcinoma (HCC)

    phase 3 small molecule active

    1 trial

  24. Tecentriq 1 200 mg concentrate for solution for infusion, Avastin 25 mg/ml concentrate for solution for infusion.

    Ningbo Cancer Hospital

    Metastatic (stage IVB), Persistent, or Recurrent Carcinoma of the Cervix

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources